Singapore
The firm has closed more than five mandates with Asian LPs in the past year.
1
India: Healthtech startup Ultrahuman raises $70m from Qualcomm, others
2
KKR to acquire minority stake in Malaysia's Avisena Healthcare
3
India's Swiggy pares gains ahead of exit from MSCI indexes
4
Bilibili to raise $700m via convertible notes; Tencent to subscribe
5
Armed with over $15b in cash, Shein seeks deals to spur growth
More Stories
Beyond the Buyout: China’s USD fundraising is back, but it has a catch
Blue Pool Capital, others said to have invested in DatViet’s IPO
Ex-BRI Ventures chief Nicko Widjaja loses appeal in TaniHub case
Morgan Stanley PE Asia explores Omega-ClearMedi merger in India
Malaysia’s finance ministry hires adviser to assess AirAsia’s funding needs
The firm focuses on India, Australia, and SE Asia.
Rest of Asia
Asian target could bring bigger presence or more clients, William Huffman says.
The firm is in discussions to hire a Partner in Singapore.
Greater China
This gives it an edge over traditional Western pharmaceutical giants.
The firm also sees opportunities in the mid-market space in Japan.
Infrastructure as an asset class has typically been generating stable, long-term returns.
The firm’s private wealth AUM hit $17.8 billion by March 31, 2026.
It is also on track to close its second PE Fund.
The fintech sees stablecoins becoming an increasingly visible part of global money movement.
